Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Impatto della regolazione delle emozioni dei genitori sul trattamento dell'ADHD (PERS)

30 settembre 2026 aggiornato da: James Waxmonsky, Milton S. Hershey Medical Center

L'impatto della capacità di regolazione delle emozioni dei genitori sul trattamento comportamentale per l'ADHD pediatrico

Aim: To examine if parental emotion regulation (ER) moderates the response to parent training interventions.

H1: Reduced parental ER capacity will predict diminished efficacy for behavioral parent training to improve negative parenting behavior (NPB) and behavior problems in offspring with ADHD.

H2: Increased parental emotional reactivity will predict diminished efficacy for behavioral parent training to improve negative parenting behavior (NPB) and behavior problems in offspring with ADHD.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

Children ages 5-12 with ADHD and at least a mild level of oppositional behaviors will be enrolled in a single arm study examining the impact of objective and self rated measurements of parental emotion regulation and emotional reactivity to predict the degree of improvement seen in children's oppositional behaviors and negative parenting behaviors and from an evidence based eight session parenting intervention. The program emphasizes attending to positive behavior, contingent rewards for good behaviors and predictable consequences, such as time-out or loss of privilege, for negative behaviors. The primary outcome is change in parent ratings of symptoms of Oppositional Defiant Disorder (ODD) as measured by the Disruptive Behaviors Disorder Rating Scale (DBDRS).Negative parenting behaviors (NPB) will be assessed using the Alabama Parenting Questionnaire which measures five different domains of parenting and has been used in past trials to detect changes in NPB. Measures will be collected at baseline, midpoint and endpoint. Parental ER capacity will be examined as moderators of the treatment effect on children's symptom levels and NPB.

We will employ two measures of parental emotion regulation: self report using the Difficulties with Emotion Regulation Scale (DERS) and the change in amplitude on the late positive potential (LPP) during an emotion regulation task. The total score from the DERS collected at baseline will serve as the self report measure of parental ER. The total score is the sum of the 6 DERS subscales: nonacceptance of emotional responses, difficulties engaging in goal directed behavior, impulse control difficulties, lack of emotional awareness, limited emotion regulation strategies and lack of emotional clarity.

A cognitive reappraisal task completed under EEG monitoring will serve as the neurobiological measurement of emotion regulation capacity. Change in LPP amplitude on this task has been well established as measure of regulatory capacity. The stimulus set will be comprised of 30 unpleasant, high arousing and 30 neutral, low arousing images from the International Affective Picture System (IAPS). The study will consist of 1 block of 90 stimuli with three types of randomly ordered trials within the block. There will be 30 trials each of a "look neutral", "look negative" and "decrease negative" trial (described below). On each trial, participants will first be asked to relax (baseline) prior to seeing a cue word for 2 seconds on the screen telling them either to "look" or "decrease." After the cue word, a fixation cross to orient visual attention is shown for 500ms, followed by the stimulus for 6 seconds. After each picture, participants will rate their level of arousal on a 0-7 likert. There will be a 2.5 second pause between trials. Prior to data collection, there will be two practice blocks. In the first, participants are given explicit instructions on what to do during the look and decrease trials, with examples of appropriate reappraisal. For 5 practice trials, they will be given detailed feedback on their appraisal efforts. The second practice will consist of 10 trials mimicking the exact procedures for the real task (no feedback). Emotion regulation capacity will be defined as the change in the LPP amplitude between the "look negative" and "decrease negative" trials, with "look neutral" vs look negative" serving as reference comparison to measure the participants' reactivity to emotional stimuli. Total task time is estimated to be 20-22 minutes. On the "decrease negative" trials, participants will be advised to create a positive frame for the story in order to feel negative emotions less strongly. For example, if shown a picture of a corpse, one could imagine that a crime had been solved preventing future murders. In the "look negative" trials, participants will be advised not to perform any reappraisal and simply rate the picture as they see it. In all trials, participants will be instructed only to think about the picture and not to intentionally distract themselves.

Electroencephalogram (EEG) data will be recorded using a 32-channel BrainProducts actiCHamp system and BrainVision Recorder software with electrodes placed over the left and right mastoids as reference electrodes, and above and below the eyes to measure the electrooculogram. The EEG signal will be digitized at 24-bit resolution and sampled at 500 Hz. Data will be processed using BrainVision Analyzer software, and segmented 200ms prior to stimulus onset and continuing for the 6 sec stimulus duration. Data will be referenced to the mastoid averages, filtered from .01 to 30 Hz, and corrected for artifacts. Event-related brain potentials (ERPs) will be constructed by separately averaging "look neutral", "look negative" and "decrease negative" trials for each recording site. The average activity in the 200ms window prior to cue onset will be the baseline. LPP amplitude will be defined as the average amplitude at central-parietal electrodes where LPP is maximal. Consistent with prior work and to evaluate changes in LPP across time as a function of reappraisal, LPP will be examined in in frontal and parietal sites at early (400 to 700ms after image onset), middle (700 to 1000ms) and late (1000 to 6000ms) time windows. Mean LPP amplitudes will be exported from BrainVision and evaluated with SPSS.

After completing this task, participants will also complete the Emotional Faces Task while undergoing EEG assessment using the same EEG techniques and ERP outcomes described above to measure the neurophysiological response to emotions (emotional reactivity). During the task, participants will view images of children with angry or neutral emotional expressions from the NIMH child faces stimulus set or pixelated faces in which the expression is unclear. Following the emotional face, an arrow (< or >) briefly appears on the screen and participants are instructed to press a mouse button to correspond with the direction of the arrows in order to ensure participants are attending to the images. Finally, the same emotional face is presented briefly so that the arrow appears between presentations of the same stimulus. Participants will first complete a brief practice block and then will view complete the emotional faces task. Consistent with prior work measuring reactivity to facial stimuli, LPP change between angry and pixleated faces will be examined in in occipital and parietal sites between 300 to 1000ms after image onset.

This study will examine if parental emotion regulation capacity is associated with the degree of symptomatic improvement in children's oppositional behaviors and negative parenting behaviors (NPB) following a course of behavioral parent training, and whether this association is moderated by parent emotional regulation or parent emotional reactivity. It is hypothesized the association between negative parenting behaviors will be more strongly associated with negative child behavior for parents with lower capacities for emotion regulation (as measured by smaller changes in LPP amplitude/higher scores on the DERS). This hypothesis will be tested by computing multilevel model, with treatment (pre, post) as the level 1 (within-subjects) predictor and parent ER as the level-2 (between-subjects) predictors, along with parent and child demographics as covariates. Separate analyses will be conducted for child and parent outcomes. Analyses will then be repeated using the objective measure of parental emotional reactivity (LPP amplitude change during the faces task) as the moderator in place of parental emotional regulation capacity.

Tipo di studio

Interventistico

Iscrizione (Stimato)

65

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 5 anni a 12 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Parent of a child ages 5-12 with ADHD
  • Parent must report that the child has at least a mild level of symptoms at home of Oppositional Defiant Disorder (ODD) on the Disruptive Behavior Disorder Rating Scale (DBDRS)

Exclusion Criteria:

  1. Not being the parent of a child ages 5-12 who meets diagnostic criteria for ADHD.
  2. Non English Speaking
  3. the child with ADHD has a diagnosis of intellectual delay or has prominent autistic traits
  4. Another child in the same family participating in this study already
  5. Parent does not have a smartphone or tablet device to complete EMA ratings or does not reside with child for the majority of the time.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Behavior Therapy

8 sessions of an evidence based parenting program to address oppositional behaviors and ADHD symptoms at home. All participants are in this arm.

8 session evidence based parenting intervention

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Oppositional Defiant Disorder Symptoms (change from baseline to endpoint)
Lasso di tempo: baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))

This will be measured using parent ratings of symptoms of Oppositional Defiant Disorder as rated on the Disruptive Behavior Disorder Rating Scale (DBD-RS). The Oppositional Behavior subscale on the DBD-RS measures 8 items rated 0-3. Items are averaged to create a mean total score between 0-3. Higher scores indicate greater impairment and worse outcomes.

baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in ADHD symptoms (change from baseline to endpoint)
Lasso di tempo: baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))

This will be measured using parent ratings of symptoms of ADHD as rated on the Disruptive Behavior Disorder Rating Scale. The ADHD symptom subscale on the DBD-RS has 18 items rated 0-3 that are averaged to create a mean total score (0-3). Higher scores indicate greater impairment and worse outcomes.

baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))
Change in Conduct Disorder Symptoms (change from baseline to endpoint)
Lasso di tempo: baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))

This will be measured using parent ratings of symptoms of Conduct Disorder as rated on the Disruptive Behavior Disorder Rating Scale (DBD-RS). The Conduct Disorder subscale on the DBD-RS conduct scale has 15 items rated 0-3 that are averaged to create a mean total score (0-3). Higher scores indicate greater impairment and worse outcomes.

baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))
Change in Irritability symptoms (change from baseline to endpoint)
Lasso di tempo: baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))

This will be measured using parent ratings of symptoms of irritability as rated on the Disruptive Behavior Disorder Rating Scale (DBD-RS). The Irritability symptom subscale on the DBD-RS has 3 items rated 0-3. They are averaged to create a mean total symptom score (0-3). Higher scores indicate greater impairment and worse outcomes.

baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))
Change in rates of Poor Monitoring from Baseline (before therapy) to Endpoint (after last therapy session)
Lasso di tempo: baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))

This will be measured using parent self-report ratings of poor monitoring as rated on the Alabama Parenting Questionnaire (APQ). The Poor Monitoring subscale on the APQ has 10 items rated 1-5. They are summed to create a total score. Higher scores indicate greater impairment and worse outcomes.

baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))
Change from Baseline (before therapy) Inconsistent Discipline at Endpoint (after last therapy session)
Lasso di tempo: baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))

This will be measured using parent self-report ratings of inconsistent discipline as rated on the Alabama Parenting Questionnaire (APQ). The Inconsistent Discipline subscale on the APQ has 6 items rated 1-5. Scores from each item are summed to create a total score. Higher scores indicate greater impairment and worse outcomes.

baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))
Change from Baseline (before therapy) Corporal Punishment at Endpoint (after last therapy session)
Lasso di tempo: baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))

This will be measured using parent self-report ratings of corporal punishment as rated on the Alabama Parenting Questionnaire (APQ). This subscale on the APQ has 3 items rated 1-5. Scores from each item are summed to create a total score. Higher scores indicate greater impairment and worse outcomes.

baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))
Change from Baseline (before therapy) Parental Involvement at Endpoint (after last therapy session)
Lasso di tempo: baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))

This will be measured using parent self-report ratings of parental involvement as rated on the Alabama Parenting Questionnaire (APQ). The Poor Monitoring subscale on the APQ has 10 items rated 1-5. Scores from each item are summed to create a total score. Higher scores indicate greater impairment and worse outcomes.

baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))
Change from Baseline (before therapy) Positive Parenting at Endpoint (after last therapy session)
Lasso di tempo: baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))

This will be measured using parent self-report ratings of positive parenting as rated on the Alabama Parenting Questionnaire (APQ). This subscale on the APQ has 6 items rated 1-5. Scores from each item are summed to create a total score. Higher scores indicate greater impairment and worse outcomes.

baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))
Change from Baseline (before therapy) Overall Impairment at Endpoint (after last therapy session)
Lasso di tempo: baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))

This will be measured using parent ratings of overall impairment as rated on the Impairment Rating Scale (IRS). The Overall Impairment subscale on the IRS has a minimum score of 0 and maximum score of 6. Higher scores indicate greater impairment and worse outcomes.

baseline (week 0 prior to first therapy session), endpoint (after 8th therapy session which on average is 12 weeks later ))

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

13 aprile 2017

Completamento primario (Stimato)

30 giugno 2027

Completamento dello studio (Stimato)

31 agosto 2027

Date di iscrizione allo studio

Primo inviato

10 febbraio 2022

Primo inviato che soddisfa i criteri di controllo qualità

18 marzo 2022

Primo Inserito (Effettivo)

29 marzo 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi